Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Old Patients With Breast Cancer
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 345
- Primary Endpoint
- Assessment of the prevalence of gene mutations in women <=35 years old with early breast cancer.
Study Overview
Brief Summary
Age may pertain to different tumor genotype characteristics which may interfere with treatment efficacy and prognosis. The investigators investigated the distribution and prognostic effect of mutations (mut) and tumor infiltrating lymphocyte (TILs) in young and elderly early breast cancer patients (pts).
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •women with early breast cancer <35 years old or >65 years old
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Assessment of the prevalence of gene mutations in women <=35 years old with early breast cancer.
Time Frame: Up to 13 years
Assessment of the prevalence of gene mutations in women >65years old with early breast cancer.
Time Frame: Up to 13 years
Evaluation of Tumor Infiltrating Lymphocytes (TILs) density using descriptive statistics in women <=35 years old with early breast cancer.
Time Frame: Up to 13 years
Evaluation of Tumor Infiltrating Lymphocytes (TILs) density using descriptive statistics in women >65 years old with early breast cancer.
Time Frame: Up to 13 years
Evaluation of the prognostic effect of gene mutations and Tumor Infiltrating Lymphocytes with respect to Overall Survival in women <=35 years old with early breast cancer
Time Frame: Up to 13 years
Evaluation of the prognostic effect of gene mutations and Tumor Infiltrating Lymphocytes with respect to Overall Survival in women >65 years old with early breast cancer.
Time Frame: Up to 13 years
Secondary Outcomes
No secondary outcomes reported
Investigators
Manto Nikolaidi
Medical Oncologist
Hellenic Cooperative Oncology Group